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Abstract
Background: Outbreaks of invasive pneumococcal disease (IPD) typically occur within institutions. Beginning in 2005, we
detected an increase in serotype (ST) 5 and ST8 IPD cases, predominantly in homeless persons living in an open community.
Methodology/Principal Findings: CASPER (Calgary Area S. pneumoniae Epidemiology Research) surveillance study of all
IPD (sterile site isolates) in our region (pop ,1,100,000). Interviews and chart reviews of all cases and all isolates
phenotypically analyzed and selected isolated tested by multi-locus sequence typing (MLST).
Conclusions/Significance: During 2005–2007, 162 cases of ST5 IPD and 45 cases of ST8 IPD were identified. The isolates
demonstrated phenotypic and genotypic clonality. The ST5 isolates were sequence type (ST) 289 and demonstrated
intermediate susceptibility to TMP-SMX. The ST8 isolates were predominantly ST1268, with a susceptible antimicrobial
susceptibility profile. Individuals with ST5 IPD were more likely to be middle aged (OR 2.6), homeless (OR 4.4), using illicit
drugs(OR 4.8), and asthmatic(OR 2.6). Those with ST8 were more likely to be male (OR 4.4), homeless (OR 2.6), aboriginal
(OR7.3), and a current smoker (OR 2.5). Overlapping outbreaks of ST5 and ST8 IPD occurred in an open community in
Calgary, Canada and homelessness was a predominant risk factor. Homelessness represents a unique community in which
pneumococcal outbreaks can occur.
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Introduction
Streptococcus pneumoniae (pneumococcus) is a leading cause of
morbidity and mortality worldwide. Bacteremia, meningitis and
pneumonia are the most common manifestations of invasive
pneumococcal disease (IPD). Otitis media, sinusitis and non-
bacteremic pneumonia are the most common noninvasive
forms.
Outbreaks due to pneumococcus have been most frequently
described in ‘‘closed’’ institutional settings,with the presence of
crowding (hospital wards, nursing homes, day care centers)
[1,2,3,4,5,6,7]. Some pneumococcal serotypes are more frequently
associated with outbreaks, including serotypes 1, 2, 4, 5, 9V, 12F,
14 and 23F [8].
We describe two large outbreaks of IPD in Calgary, Alberta,
caused by serotypes 5 and 8 (ST5, ST8. These outbreaks took
place in the community, but preferentially affected specific
populations. The early features of these outbreaks were previously
reported [9,10]. The ST5 outbreak spread across western Canada
and some features have been reported elsewhere [11,12,13].
Methods
Outbreak investigation
Active, population-based surveillance of IPD has been conduct-
ed in the city of Calgary and surrounding area since January 1,
1998 by the Calgary Area Streptococcus pneumoniae Epidemiology
Research (CASPER) team [14]. The area is an integrated, publicly
funded health region (Calgary Health Region, CHR) that includes
the hospitals and outpatient facilities within the city of Calgary, as
well as medical centres serving rural areas surrounding the city
(population 1,111,614 in 2007).
Patients were deemed to be CHR residents on the basis of home
postal code listed in the admission and laboratory records. If this
information was unavailable, patients with provincial health care
numbers were considered to be CHR residents if the culture
specimen was submitted to a collection site within the CHR
boundaries. This study was approved by the Conjoint Health
Research Ethics Board of the University of Calgary and written,
informed consent was obtained from persons with IPD were
enrolled in the study.
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sterile body fluids) are identified through active laboratory
surveillance in Calgary Laboratory services (CLS), a centralized
laboratory service that provides clinical microbiology services to all
hospitalized and ambulatory patients in the CHR. Although IPD
is a notifiable disease in Alberta requiring notification of local
public health officials of all cases to permit appropriate public
health follow-up and reporting (passive surveillance), the CASPER
surveillance project is separate from public health and collects
more detailed information on cases and organisms.
For all IPD cases since 2003, a patient interview was conducted
as well as a detailed chart review for all cases for 30 days after the
diagnosis. Demographic and pre-existing health status information
was collected, as were details of the clinical course and outcome.
Increased cases of serotype specific IPD (serotypes 5 and 8) were
identified, starting in 2005 for ST8 and 2006 for ST5. These cases
occurred only in adults so the analysis in this manuscript includes
only persons aged 16 years or more.
The cases of ST5 IPD occurred frequently in the homeless
population and a targeted intervention was directed to try to
control transmission. A one-week vaccination campaign, with the
23-valent pneumococcal polysaccharide vaccine (PPV23), was
conducted by the CHR Public Health program in December
2006. The PPV23 was offered at several homeless shelters and
Table 1. Total Annual Cases of Invasive Pneumococcal
Disease (IPD) and ST5 and ST8 IPD Cases from 1998 to 2008,
Calgary, AB.
Year
Total IPD
Cases (n)
ST5 IPD Cases
(n,%)
ST8 IPD Cases
(n,%)
1998 91 0 (0.0) 0 (0.0)
1999 95 0 (0.0) 1 (1.0)
2000 98 0 (0.0) 4 (4.1)
2001 135 1 (0.7) 5 (3.7)
2002 101 1 (1.0) 3 (3.0)
2003 109 0 (0.0) 6 (5.5)
2004 90 0 (0.0) 9 (10.0)
2005 114 7 (6.1) 22 (19.3)
2006 157 64 (40.8) 12 (7.6)
2007 188 91 (48.4) 11 (5.8)
2008 119 12 (10.1) 5 (4.2)
2009 85 3 (3.5) 1 (1.2)
Total 1382 179 (12.9) 79 (5.7)
doi:10.1371/journal.pone.0028547.t001
Figure 1. Incidence of Invasive Streptococcus pneumoniae Infections, highlighting outbreaks with serotype 5 and 8, in the Calgary
Health Region, 1998–2009.
doi:10.1371/journal.pone.0028547.g001
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In the autumn of 2006, before the outbreak, 339 doses of
pneumococcal vaccine had been provided to the homeless
population, as that group was newly considered eligible for
vaccine in the province. The outbreak was determined to be over
5–6 months later when the number of cases returned to baseline.
During, the vaccine campaign, a survey to determine nasopha-
ryngeal colonization with pneumococcus, with a brief question-
naire, was performed at the main homeless shelter in Calgary.
Pneumococcal isolates obtained from this survey were also tested
for antibiotic susceptibility and serotype.
Definitions
Aboriginal status was determined by patient interview and chart
review.
Sepsis was defined as a systemic response to infection in the
context of confirmed evidence of IPD. The systemic response was
manifested by two or more of the following: temperature .38uC
or ,36uC, white blood cell count .12,000/mL, ,/mL 4000/mL
or 10% immature forms (bands), heart rate .90 beats per minute
or a respiratory rate .20 breaths per minute or arterial CO2
tension ,32 mmHg.
Septic shock was defined as sepsis associated with organ
dysfunction: hypotension despite adequate fluid resuscitation
and requiring use of vasoactive drugs, defined by systolic blood
pressure greater than or equal to 90 mmHg; metabolic
acidosis; oliguria; hypoxia, not explained by primary respira-
t o r yd i s t r e s s ;c o n f u s i o n ;r e n a li m p a i r m e n t ,c r e a t i n i n e./=to
177 mmol/L outside the context of pre-existing renal disease;
coagulopathy, evidenced by platelets #100,000/mm
3610
6/L,
and/or evidence of disseminated intravascular coagulation
(defined by prolonged clotting times,) low fibrinogen level,
and/or the presence of five and degradation products); liver
involvement, alanine aminotransferase (ALT), aspartate ami-
notransferase (AST), total bilirubin greater than or equal to
twice the upper limit of normal; or acute respiratory distress
syndrome.
Laboratory methods
Isolates were confirmed to be pneumococcus by standard
methodology including Gram stain, colonial morphology on blood
agar, bile solubility, susceptibility to Optochin and pneumococcal
antibody agglutination (Phadebact Pneumococcus, Boule Diag-
nostic AN, Sweden). Susceptibility testing was performed by broth
microdilution (PML Microbiologicals, bioMe ´rieux Canada, Inc.St.
Laurent , QC, Canada) and results were interpreted according to
Clinical and Laboratory Standards Institute (CLSI) guidelines
[15,16,17,18].
For the NP colonization survey at the homeless drop-in centre, a
single NP swab was obtained from each participant, using the
WHO recommended procedure [19]. Questionnaires were
administered by trained nursing personnel.
Figure 2. Epidemic Curve of Streptococcus pneumoniae Serotype 5 Outbreak in Patients Greater Than 16 Years of Age, Calgary
Health Region, 2005–2007.
doi:10.1371/journal.pone.0028547.g002
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of commercial antisera obtained from the Statens Seruminstitut
(Copenhagen, Denmark) at the National Centre for Streptococ-
cus (Edmonton, Canada). Five isolates of each ST5 and ST8
(chosen from the chronologic list of isolates analyzing the first,
last and the beginning of each quartile) were analyzed by
multilocus sequence typing (MLST) at CLS. The sequences of the
internal fragments of the 7 housekeeping loci used in the
pneumococcal MLST scheme were determined for each isolate,
as described elsewhere [20].
Data Analysis
Data were analyzed using SPSS 16.0 [SPSS Inc., Chicago] and
SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Categorical data
Figure 3. Epidemic Curve of Streptococcus pneumoniae ST8 Outbreak in Patients Greater Than 16 Years of Age, Calgary Health
Region, 2005–2007.
doi:10.1371/journal.pone.0028547.g003
Table 2. Demographic features of IPD in patients 16 years of age or older before, during and after serotype 5 & 8 outbreaks,
Calgary Health Region 2000–2007, univariate analysis.
All IPD (less ST5 &
ST8) (2000–2007) n
(%) , N=596
Outbreak ST5 cases
(2005–2007) n (%),
N=160
P Value (Fisher’s) -
ST5
1, OR (95% CI)
Outbreak ST8 cases
(2005–2007) n (%),
N=44
P Value (Fisher’s) - ST8
2,
OR (95% CI)
Demographics
Full clinical review 586 (98%) 156 (98%) 44 (100%)
Sex (male) 319 (54%) 106 (68%) 1.8 (1.2–2.6) 36 (82%) 3.8 (1.7–8.4)
Age 16–64 years 380 (65%) 150 (96%) 13.6 (5.9–31.2) 36 (82%) 2.9 (1.3–6.5)
Homeless 55 (9%) 82 (53%) 10.7 (7.0–16.3) 19 (43%) 7.3 (3.8–14.2)
Aboriginal 36 (6%) 23 (14%) 2.6 (1.5–4.6) 15 (34%) 7.9 (3.9–16.1)
1Compared to all IPD less ST5 & ST8.
2Compared to all IPD less ST5 & ST8.
doi:10.1371/journal.pone.0028547.t002
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summarized as means with standard deviations (SD). Comparisons
were made between IPD cases caused by serotypes 5 and 8 and
IPD cases caused by other serotypes. Differences between groups
were tested by the Chi-Square test and Fisher’s exact test for
categorical variables and the Student’s t-test for continuous
variables. Multivariate logistic regression was performed to
determine factors associated with either ST5 or ST8 cases over
the study period. Only those traits that were possibly significant
(P#0.10) in univariate analysis were included in the multivariate
model. Significance in the multivariate model was determined by a
p-value of ,0.05. Odds rations (OR) and 95% confidence
intervals (95% CI) are reported.
Results
A total of 1382 laboratory confirmed cases of IPC occurred in
the CHR from January 1998 to December 2008. There was an
average of 118 cases per year (Table 1). The annual incidence of
IPD is shown in Figure 1. Figures 2 and 3 show the number of
cases of serotypes 8 and 5 IPD monthly, respectively, for the
defined outbreak period from 2005 to 2007. During this period,
162 cases of IPD due to ST5 and 45 cases of ST8 occurred.
Table 2, 3, 4 describes the features of ST5 and ST8 IPD cases
from 2005 to 2007, each compared with all other IPD cases
from 2000 to 2007, in persons ./=16 years of age.. Table 5
describes the multivariate logistic regression analysis of demo-
graphic features, risk conditions and outcomes associated with
serotypes 5 and 8 cases for all cases where complete was
available.
The ST5 isolates demonstrated phenotypic and genotypic
clonality during the outbreak. All isolates were susceptible to
penicillin, erythromycin and ceftriaxone and all had intermediate
susceptibility to trimethoprim-sulfamethoxazole (TMP-SMX). The
MLST analysis of 5 representative ST5 isolates identified that all
were sequence type ST289. This is similar to the previously
described strain from Columbia also described by the Pneumo-
coccal Molecular Epidemiology Network (Columbia
5-19 strain)
[21,22,23].
The ST8 isolates also demonstrated phenotypic and genotypic
clonality during the outbreak. All isolates were susceptible to
penicillin, erythromycin, ceftriaxone and TMP-SMX. The MLST
analysis of 5 representative isolates identified sequence type
ST1480 for the first isolate and ST1268 for the remaining 4
isolates.
During the targeted PPV23 vaccine campaign in the homeless
shelters , 91 individuals (79 clients and 12 staff) at the main
Calgary homeless shelter were enrolled in the nasopharyngeal
colonization survey. The questionnaire was completed by 71
clients (89%) and 8 staff (67%). Pneumococcus was isolated from
Table 3. Clinical features and Outcome of IPD in patients 16 years of age or older before, during and after serotype 5 & 8
outbreaks, Calgary Health Region 2000–2007, univariate analysis.
All IPD (less ST5 & sT8)
(2000–2007) n (%)
Outbreak ST5 cases
(2005–2007) n (%)
P Value
(Fisher’s) – ST5
3
Outbreak ST8 cases
(2005–2007) n (%)
P Value
(Fisher’s) - ST8
4
Inpatient 535 (91%) 138 (88%) 0.05
5 35 (80%) 0.01
6
Emergency visit only 40 (7%) 11 (7%) 5 (11%)
Treated as outpatient 5(1%) 6 (4%) 2 (5%)
Never seen at hospital 6 (1%) 1 (1%) 2 (5%)
Meningitis 33 (6%) 1 (1%) 0.05
7 3(7%) 0.87
8
Pneumonia 476 (81%) 151 (97%) 37 (84%)
Bacteremia only 62 (11%) 3 (2%) 3 (7%)
Other IPD
9 15 (3%) 1 (1%) 1 (2%)
Sepsis 1st 72 hrs 565 (96%) 152 (97%) ns 42 (95%) ns
10
Severe sepsis 260 (44%) 75 (48%) ns 20 (45%) ns
Septic shock 49 (8%) 9 (6%) ns 2 (5%) ns
Outcome P Value P Value
Mean hospital days 13.1 (0–233) 11.8 (0–72) ns 10.3 (0–138) ns
Discharged home 361 (62%) 102 (65%) ,0.01
11 23 (52%) ,0.01
12
Left against medical advice 15 (3% ) 14 (9%) 5 (11%)
Died – IPD
13 84 (14%) 5 (3%) 3 (7%)
3Compared to all IPD less ST5 & ST8.
4Compared to all IPD less ST5 & ST8.
5X
2 test only, for treatment location.
6X
2 test only, for treatment location.
7X
2 test only, for clinical syndrome.
8X
2 test only, for clinical syndrome.
9Other IPD=sterile site culture other than CSF, pleural or Blood.
10not significant (P.0.15).
11X
2 test only, for disposition.
12X
2 test only, for disposition.
1330 day mortality.
doi:10.1371/journal.pone.0028547.t003
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serotypes were identified: 28A (isolates); 17F (2 isolates); and 1
each of serotypes 5, 10A 10F, 11F, 12F, 23A, 3 and 38; and 2
isolates were non-typable. Table 6 describes data obtained from
the NP colonization survey.
Discussion
Outbreaks of Streptococcus pneumoniae have been described in
closed populations such as hospitals, daycares, schools, military
barracks, nursing homes and prisons [1,2,3,4,5,6,7]. The ST5
outbreak in Calgary and across Western Canada is the first one
described in a disadvantaged but relatively open community [13].
The outbreak in Calgary area began before the outbreak in
Vancouver as described by Romney and colleagues [13]. In
addition to the ST5 outbreak, there was an outbreak of ST8 IPD
in Calgary that peaked in 2005, the year that an increase in ST5
cases began. This is the first described outbreak of ST8 IPD.
Overlapping outbreaks of this kind have not been previously
described.
Disadvantaged populations including aboriginals, homeless and
impoverished people suffer higher rates of pneumococcal disease
[24,25]. Outbreaks, however, have rarely been described in these
populations [13,26]. Mercat and colleagues described an outbreak
in homeless shelters in Paris in the late 1980s due to serotype 1
[26].
Both of the outbreaks occurred predominantly in persons at
increased risk for IPD, although the particular factors differed for
each serotype. The ST5 cases were more common in homeless
persons and those reporting illegal drug use, while the ST8 cases
were more common in males, homeless persons and aboriginals.
The Calgary homeless population was estimated at 4,060 in 2008
and this number had increased 18% from 2006 [27]. This
population is predominantly male (78%), caucasian (62%) with
29% between the age of 45 and 64 [27]. Eighteen percent of
individuals in a survey in a subset of the population had been
Calgary less than 1 year [28]. Self reported substance abuse in the
homeless population was 85% and 24% had mental health issues
[28].
Vaccination rates have traditionally been quite low in
disadvantaged populations especially those who do not seek
regular medical care. In August 2006 the Alberta Advisory
Committee on Communicable Diseases recommended offering the
23-valent polysaccharide pneumococcal vaccine to homeless
individuals and also those who are hepatitis C positive, and this
position was further strengthened by a statement from the
National Advisory Committee on Immunization in 2008 [29].
Both of the outbreak strains are be covered by the 23 valent
Table 4. Risk Factors of IPD in patients 16 years of age or older before, during and after serotype 5 & 8 outbreaks, Calgary Health
Region 2000–2007, univariate analysis.
All IPD (less ST5 &
ST8) (2000–2007)
n (%), N=596
Outbreak ST5
cases (2005–2007)
n (%), N=160 OR (95% CI)
Outbreak ST8 cases
(2005–2007) n (%),
N=44 OR (95% CI)
Current Smoker
14 328 (56%) 129 (83%) 3.8 (2.4–5.9) 40 (91%) 7.9 (2.8–22.3)
Alcoholism 124 (21%) 88 (56%) 4.8 (3.3–7.0) 21 (48%) 3.4 (1.8–6.4)
Illegal Drugs 60 (10%) 84 (54%) 10.2 ( 6.8–15.5) 14 (32%) 4.1 (2.1–8.1)
OTC Drugs 7 (1%) 3 (2%) 1.6 (0.4–6.4, ns) 0
HIV/AIDS 22 (4%) 14 (9%) 2.5 (1.3–5.1) 3 (7%) 1.9 (0.5–6.5)
Hepatitis A or B 6 (1%) 6 (4%) 3.9 (1.2–12.2) 1 (2%) 2.3 (0.3–19.1)
Hepatitis C 51 (9%) 44 (28%) 4.1 (2.6–6.5) 6 (14%) 1.7 (0.7–4.1)
Congestive Heart Failure 46 (8%) 2 (1%) 0.2 (0.04–0.6) 4 (9%) 1.2 (0.4–3.4)
Coronary Artery Disease 73 (12%) 2 (1%) 0.1 (0.02–0.4) 7 (16%) 1.3 (0.6–3.1)
Hypertension 141 (29%) 10 (6%) 0.2 (0.1–0.4) 6 (14%) 0.5 (0.2–1.2)
Congenital Defects 1 (0%) 1 (1%) 0.4 (0.2–60.7) 0
Asthma 53 (9%) 22 (14%) 1.7 (0.97–2.81) 5 (11%) 1.3 (0.5–3.4)
COPD 109 (19%) 17 (11% 0.5 (0.3–0.9) 6 (14%) 0.7 (0.3–1.7)
Cancer ,5 y ago 81 (14%) 3 (2%) 0.1 (0.04–0.4) 2 (5%) 0.3 (0.07–1.3)
Cancer .5 y ago 30 (5%) 3 (2%) 0.4 (0.1–1.2) 0 n/a
Bone Marrow Transplant 11 (2%) 0 n/a 0 n/a
Asplenia 12 (2%) 0 n/a 0 n/a
Rheumatoid Arthritis 15 (3%) 0 n/a 0 n/a
Systemic Lupus Erythematosis 13 (2%) 0 n/a 0 n/a
Chronic Renal Failure 28 (5%) 2 (1%) 0.3 (0.06–1.1) 2 (5%) 1.0 (0.2–4.1)
Diabetes 76 (13%) 5 (3%) 0.2 (0.09–0.6) 6 (14%) 1.1 (0.4–2.6)
Hypothyroidism 38 (6%) 2 (1%) 0.2 (0.05–0.8) 1 (2%) 0.3 (0.05–2.5)
Epilepsy or other seizure disorder 16 (3%) 3 (2%) 0.7 (0.2–2.4) 4 (9%) 3.6 (1.1–11.2)
14Missing values assumed non-smoker.
doi:10.1371/journal.pone.0028547.t004
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vaccine is limited [30,31]. The 7 valent conjugate vaccine
(PrevnarH) available at the time of the outbreak does not cover
the two outbreak strains [32]. The new 10-valent and 13-valent
conjugate pneumococcal vaccines, (the latter now in routine use
across Canada), cover these serotypes but are routinely so far only
used in pediatric patients [33].
Serotype 5 is a particularly invasive serotype with invasiveness
index 60 fold higher than some of the least invasive serotypes (3,
6A, 15) [34]. The ST5 strain has been particularly effective in this
outbreak evidenced by the significant presence across Western
Canada documented by both our jurisdiction and British
Columbia [13]. Serotype 5 was otherwise uncommon in our area
among invasive cases and in colonization surveys [35]. Serotype 8
was also uncommon among invasive isolates and accounted for
only 1 of 678 colonizing strains identified over multiple years. [35].
However, ST8 is commonly an invasive serotype [34]. The
majority of the ST8 sequence types were ST1268, with only the
very first isolate tested being slightly different (ST1480 which only
differs from ST1268 by 1 allele (spi)).
The demographic features, risk factors, clinical course and
outcome differed for both ST5 and ST8 cases of IPD, compared
with the rest of the adult cases of IPD before, during and after
the outbreaks. In addition data from the survey questionnaire
during the NP colonization survey several other factors that
may be associated with acquisition of pneumococcal disease
(Table 6), including cocaine and crack cocaine use, marijuana
use as well as the sharing of bottles cigarettes, crack pipes and
‘‘joints’’. As suggested by Romney, crack pipes and other
implements may be a route of transmission for pneumococcus
[13].
Although both of the described outbreaks had their onset in the
colder months of the year, a clear correlation between seasonality
and this outbreak were not well-established (Figures 2 & 3).
Crowding in the homeless shelters is more common in the winter
months, but shelter use remains significant throughout the year.
Outbreak control measures utilized in the Calgary area included
a vaccination campaign in the largest of the homeless shelters,
December 2006, that did not result in a rapid resolution of the
outbreak. The limited uptake of vaccine, limited vaccine
effectiveness, a persistent susceptible population and ongoing
crowding may have been factors in the persistence of the outbreak,
especially for ST5 disease.
In summary, we describe overlapping outbreaks of ST5 and
ST8 in an open homeless community. Significant risk factors that
contributed to either or both of these outbreaks included
homelessness, illicit drug use, smoking, aboriginal ethnicity and
smoking. Targeted vaccination programs, preferably with protein-
polysaccharide conjugate vaccines that reduce both pneumococcal
disease and transmission, may better control future outbreaks.
Table 5. Description of traits and risk factors among patients 16 years of age or older in a ST5 & ST8 outbreaks, Calgary Health
Region 2000–2007 in Multivariate analysis.
Odds Ratio, Outbreak ST5
cases (2005–2007) N=156 P Value
Odds Ratio Outbreak ST8
cases (2005–2007) N=44 P Value
Demographics
Sex (male) 1.30 ns
15 4.39 ,0.01
Age 16–64 years 2.59 0.06 0.95 ns
Homeless 4.41 ,0.01 2.58 0.02
Aboriginal 0.93 ns 7.34 ,0.01
Pre-existing Risk Factors
Current Smoker
16 1.32 ns 2.51 0.04
Alcoholism 1.50 ns 0.61 ns
Illegal Drugs 4.80 ,0.01 2.17 0.07
HIV/AIDS 0.47 0.11 n/a
Hepatitis A or B 0.87 ns n/a
Hepatitis C 0.87 ns n/a
Congestive Heart Failure 0.44 ns n/a
Coronary Artery Disease 0.36 ns n/a
Hypertension 0.69 ns n/a
Asthma 2.63 0.01 n/a
COPD 1.21 ns n/a
Cancer ,5 y ago 0.36 0.11 n/a
Chronic Renal Failure 1.23 ns n/a
Diabetes 0.40 0.11 n/a
Hypothyroidism 0.85 ns n/a
Epilepsy or other seizure disorder n/a n/a 2.66 ns
15not significant (P.0.15).
16Missing values assumed non-smoker.
doi:10.1371/journal.pone.0028547.t005
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